The Ohio State University

•

Channel • 25 Shows

Earth Sciences

Earth Sciences

Monthly
Education

Education

Monthly
Society & Culture

Society & Culture

Series
Education

Education

Twice monthly
Self-Improvement

Self-Improvement

Monthly
Politics

Politics

Updated weekly
History

History

Updated 18/12/2025

03/03/2020

Episode 51: What You Need to Know About Cancer, with David Cohn, MD

Cancer science is complicated, but David Cohn, MD, The James' chief medical officer, breaks it all down during this easy-to-understand conversation. Learn about cancer cells, how they grow and spread and its different stages. Also, Cohn explains some of the ways cancer is treated — surgery, radiation, chemotherapy and immunotherapy — and how those treatments work in the body. Finally, learn how we all can help create a cancer-free world through accepted prevention practices.
08/02/2023

Malak Abdel-Hadi, MBOE Class of 2020

Laurie Spadaro, director of the Master of Business Operational Excellence (MBOE)program, sits down with Malak Abdel-Hadi, MBOE class of 2020. Malak serves as process improvement specialist for Safelite AutoGlass, a company that prioritizes process improvement. Hear how Malak switched companies and positions to best utilize her education.
08/02/2023

Ashley Donnini, EMBA Class of 2017

Anna Morris, Associate Director of Engagement, sat down with Ashley Donnini, EMBA Class of 2017, to hear why she chose to pursue her Executive MBA and how it's had an impact on her career. Since graduation, Ashley has started her own company, Lola Link Consulting, a boutique firm focused in the utility industry.
20/09/2024

Jenny Jones, EMBA Class Of 2022

In this episode, we sit down with Jenny Jones, Sr. Marketing Manager at Johnson & Johnson and 2022 graduate of the Executive MBA program at Fisher College of Business. Jenny shares her journey of deciding to pursue an Executive MBA and how the program has made a significant impact on her career and personal growth. Jenny emphasizes the importance of investing in yourself and taking that leap of faith to unlock new opportunities. Whether you're considering an advanced degree or looking for inspiration to advance in your career, Jenny's story will motivate you to take the next step.
25/05/2023

KXplores Emerging Research: Ashley tests pest management recs to aid pollinators

Long standing Integrated Pest Management strategies are getting a makeover. Specialty crop entomologist Dr. Ashley Leach is validating those practices to find out what’s still working and what might need a tweak to protect pollinators. In the project with Dr. Reed Johnson, from the Department of Entomology, they’ve discovered some off target outcomes from reduced pesticide use. And Ashley dreams big that ugly produce from the grocery store finds a place in your fridge.
25/05/2023

KXplores Emerging Research: Ashley tracks the spotted lanternfly

Invasive pest, the spotted lanternfly (SLF), has been reported in four Ohio counties and 14 U.S. states. The brightly colored red and grey leafhopper poses an economic threat to Ohio’s specialty crop producers. Entomologist Dr. Ashley Leach’s new research project detects SLF in the environment using biomonitoring, a process that tests for DNA left behind by the destructive pest. Early detection of the SLF could help producers better prepare and possibly reduce the damaging effects of SLF. Visit stopslf.org to learn how to stop the SLF.
03/12/2019

Episode 52 - Bunker and Silage Pile Safety

There are two primary risks associated with bunker silos and silage piles: a person working on top of the pile or the bunker falling off the pile/bunker, and second, a person or persons on the ground near the silo or pile being buried by a silage avalanche. All bunker silos and silage piles are not the same. Factors that should be considered when assessing safety risks are height of the silage, face management, and labor tasks. Safety measures and guidelines are discussed.
02/05/2023

Episode 138: Advances in Urologic Cancer Treatment with Dr. Eric Singer

During the past decade “the number of new drugs and the pathways that we’re targeting has expanded so much; it’s a very exciting time,” said Eric Singer, MD, a kidney cancer specialist and the new division chief for urologic oncology at the James. In this episode, Singer discusses how and why he got into medicine and oncology, why he uprooted from New Jersey to come to Ohio State, and some of the many advances in treating urologic cancers. A new clinical trial for kidney cancer patients introduces targeted therapy drugs and immunotherapy drugs to patients prior to surgery. Another clinical trial utilizes different combinations of drugs; and another clinical trial uses “adjuvant” therapy after surgery. “It’s the idea that after surgery, even though there is no evidence of cancer, we give the drugs to reduce the chance of it coming back [for high-risk patients],” Singer explained. Urologic cancers include kidney, cladder, prostate, testicular, penial and adrenal cancers. The James division of urologic oncology is growing, and Singer is actively recruiting new surgeons. “I look for someone with incredible passion and a commitment to being a great surgeon, someone who is always thinking how does this benefit the patient,” he said. Singer also talked about how cancer has impacted his family, including his sister, who passed away from ovarian cancer. “Seeing her go through it … was heartbreaking and also so inspiring,” he said, adding her journey has inspired him to go above and beyond for his patients.
17/02/2025

Episode 183: The Global One Health Initiative for Lymphoma, with Dr Robert Baiocchi

The reach of the James Cancer Hospital extends far beyond Central Ohio. As part of Ohio State’s Global One Health Initiative (GOHi), Robert Baiocchi, MD, PhD, is leading the research, vaccination and treatment efforts in Ethiopia for patients with lymphoma. “Lymphoma, a cancer of the white blood cells, is far more common in Sub-Saharan Africa, and afflicts people at a younger age” said Baiocchi, a James medical oncologist who specializes in treating patients with blood cancers. The prevalence of malaria and the Epstein-Barr virus (EBV) has led to the increased number of lymphoma diagnoses. “Starting in 2015 we opened a lab in Addis Ababa [the capital of Ethiopia] to study these viruses and how they cause cancers,” Baiocchi said, adding the initial research was to determine why the lymphoma rate was so high. “We’re zeroing in on a couple of interesting findings; children who get malaria and EBV, that seems to be the perfect storm [for lymphoma].” Differences in the genetic makeup of people in Sub-Sharan Africa could be another factor in the increased lymphoma rates. Baiocchi and his team, and their partners in Ethiopia, are working on vaccines for malaria and EBV. “Studies tell us the virus here [in the United States] is different from the viruses in Ethipia and the vaccines we use here won’t work there,” he said. “It’s important to understand the genetic makeup of EBV in order to develop a vaccine that will be effective in that region.” The standard of care at the James for lymphoma patients includes a combination of chemotherapy drugs – and has proven to be very effective. “The resources for this aren’t available in Ethiopia,” Baiocchi said, adding the James is developing a less-expensive, targeted therapy that shows promise. There are also plans to create a facility in Addis Ababa where lymphoma patients will be treated with cell therapy.
21/06/2022

Episode 115: Advances in Treating Lung Cancer, With David Carbone

When David Carbone, MD, PhD, began treating lung cancer patients in the 1980s, “it wasn’t clear if anything helped survival.” However, over the past few decades the treatment options and results “have changed dramatically,” said the director of the James Thoracic Oncology Center. In this episode of the James Cancer Free World podcast, Carbone explains the advances made over the years: precision cancer medicine that targets specific mutations, and immunotherapy drugs that “turn on” the body’s own immune system to detect and attack cancer cells that had previously been hiding. “The immune system now sees something it couldn’t see before,” Carbone said. Another promising area of research is cellular therapy in which immune cells are genetically modified to be more powerful “and then infused back into the patient.” Carbone said that new targets and therapies are being discovered in labs at the OSUCCC – James on a regular basis. “It’s important to convey to patients that there is now hope,” he said.

Discover Ohio State, a mission-driven land grant university, home to the Wexner Medical Center and world-class graduate, undergraduate and research programs.